A Longitudinal, Multi-Center Safety Study of Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears

NCT ID: NCT05400798

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

246 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a longitudinal follow-up study of the RC-002 study, in which up to 246 subjects assigned to two randomization arms will be enrolled: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to ADRC treatment or active control arms in a 2:1 ratio and will be followed up for 6 months.

The goal of the RC-004 study is to enroll all patients that were enrolled and treated in RC-002 and follow for 3 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Partial Thickness Rotator Cuff Tear

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adipose Derived Regenerative Cells

a single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear

Group Type EXPERIMENTAL

Adipose Derived Regenerative Cells

Intervention Type DEVICE

single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear

Corticosteroid

a single corticosteroid injection into the subacromial space of the index arm

Group Type ACTIVE_COMPARATOR

Corticosteroid

Intervention Type DEVICE

a single corticosteroid injection into the associated subacromial space

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adipose Derived Regenerative Cells

single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear

Intervention Type DEVICE

Corticosteroid

a single corticosteroid injection into the associated subacromial space

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Subjects must have completed RC-002.
* 2\. Subjects can give appropriate consent.

Exclusion Criteria

* 1\. Subjects who require the use of index arm for ambulation or mobilization via wheelchair, walker, crutches or cane.
* 2\. Subjects whose pain behavior or pain medication usage is, in the opinion of the Investigator, out of proportion to the underlying clinical condition or could interfere with the study-required assessments.
* 3\. Subject is on an active regimen of chemotherapy or radiation-based treatment.
* 4\. Subject is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with a mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
* 5\. Uncooperative subjects or those with neurological/psychiatric disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

InGeneron, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher Alt, MD

Role: STUDY_DIRECTOR

InGeneron, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Research Center

Phoenix, Arizona, United States

Site Status

Biosolutions Clinical Research Center

La Mesa, California, United States

Site Status

Lotus Clinical Research, LLC

Pasadena, California, United States

Site Status

Sports and Orthopedic Center

Coral Springs, Florida, United States

Site Status

Universal Axon Clinical Research

Doral, Florida, United States

Site Status

Andrews Institute for Orthopedics and Sports Medicine

Gulf Breeze, Florida, United States

Site Status

Georgia Institute for Clinical Research

Marietta, Georgia, United States

Site Status

Tulane University School of Medicine

New Orleans, Louisiana, United States

Site Status

Sanford Orthopedic Clinic/Research

Sioux Falls, South Dakota, United States

Site Status

HD Research

Houston, Texas, United States

Site Status

Texas Center for Cell Therapy and Research

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PRP in ACLR to Prevent PTOA
NCT05412381 RECRUITING PHASE3